Skip to Content
Merck

SML0425

Caspofungin diacetate

≥97% (HPLC), powder, cell wall synthesis inhibitor

Synonym(s):

1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C52H88N10O15 · 2C2H4O2
CAS Number:
179463-17-3
Molecular Weight:
1213.42
UNSPSC Code:
51283107
PubChem Substance ID:
329825420
NACRES:
NA.77

Product Name

Caspofungin diacetate, ≥97% (HPLC)

SMILES string

CC([O-])=O.CC([O-])=O.CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCC[NH3+])NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c4ccc(O)cc4)[C@H](O)CC[NH3+]

InChI

1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1

InChI key

OGUJBRYAAJYXQP-IJFZAWIJSA-N

assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

H2O: 15 mg/mL (clear solution)

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Caspofungin diacetate has been used:

  • in an antifungal susceptibility test
  • as a standard antifungal for valproic acid (VPA)-synergy assessment
  • to treat Cryptococcus neoformans strain B3501 to study natural killer (NK) cell killing of Cryptococcus in the presence of β-1,3-glucan

Biochem/physiol Actions

Caspofungin is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthase which is required for cell wall synthesis.
Caspofungin is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthase, which is required for cell wall synthesis, thereby disturbing the integrity of the fungal cell wall.
Caspofungin, aechinocandin, a lipophilic antifungal drug, and α β-1,3-D-glucan synthesis antagonist, are used in fungal cell wall biosynthesis research to study the role of β-1,3-D-glucans in cell wall integrity and fungal survival under various environmental and chemical stresses. Caspofungin is used to treat esophageal candidiasis, candida infections, febrile neutropenia, invasive candidiasis, and invasive aspergillosis.

General description

Caspofungin belongs to the echinocandins class of drugs. This drug has a limited α-phase half-life (t 1/2) of one to two hours (volume of distribution of 9.7L) and a β-phase t 1/2 of nine to 11 hours.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000436940
0000436940
0000348332
0000348335
0000342542

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sarah R Beattie et al.
mSphere, 7(3), e0016322-e0016322 (2022-05-05)
There is an urgent need for new antifungals to treat cryptococcal meningoencephalitis, a leading cause of mortality in people living with HIV/AIDS. An important aspect of antifungal drug development is the validation of targets to determine whether they are required
Joseph Meletiadis et al.
Antimicrobial agents and chemotherapy, 51(6), 2053-2064 (2007-03-28)
Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple combination of voriconazole, amphotericin B, and caspofungin against Aspergillus fumigatus, A. flavus, and A. terreus by
Liping Xiong et al.
mSphere, 9(7), e0037224-e0037224 (2024-07-09)
Iron acquisition is critical for pathogens to proliferate during invasive infection, and the human fungal pathogen Candida albicans is no exception. The iron regulatory network, established in reference strain SC5314 and derivatives, includes the central player Sef1, a transcription factor
Vanessa Dumeaux et al.
eLife, 12 (2023-10-27)
Candida albicans, an opportunistic human pathogen, poses a significant threat to human health and is associated with significant socio-economic burden. Current antifungal treatments fail, at least in part, because C. albicans can initiate a strong drug tolerance response that allows
Timothy Cairns et al.
STAR protocols, 3(4), 101883-101883 (2023-01-04)
This protocol describes procedures for quantifying Aspergillus niger growth in both solid and liquid culture. Firstly, by comparing radial growth between mutant and progenitor isolates on solid agar supplemented with sublethal stressors, susceptibility coefficients can be calculated. Secondly, analysis of
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service